ライフサイエンスコーパス: subretinal

1 ive intraocular fluids cultures (p < 0.001), subretinal abscess (p = 0.025), unilateral involvement (

2 etion protected the mice from the pathogenic subretinal accumulation of mononuclear phagocytes (MP) t

3 outer segment tip (COST) visibility, cysts, subretinal and intraretinal fluid, and epiretinal membra

4 ation of CD47 accelerated resolution of both subretinal and peritoneal inflammation, with implication

5 graphy, 83% had fluid (61% intraretinal, 38% subretinal, and 36% sub-retinal pigment epithelium).

6 erence tomography (presence of intraretinal, subretinal, and subretinal pigment epithelium fluid; thi

7 ts at higher risk of spontaneous retinal and subretinal bleeding.

8 ents with GA and show their association with subretinal CD14(+)mononuclear phagocyte (MP) infiltratio

9 orse than -6.0 diopters with the presence of subretinal/choroidal neovascularization as indicated by

10 c CNV was defined as HM with the presence of subretinal/choroidal neovascularization indicated by the

11 reduced visual acuity and bilateral diffuse, subretinal, confluent, placoid, and multifocal chorioret

12 tudy, we evaluated the epigenetic changes of subretinal delivering NP-cDNA vs. NP-sgRho in the RKO mo

13 Subretinal delivery of AAV serotype 2 (AAV2) and its hep

14 Subretinal delivery of AAV5-IRBP/GNAT2-DIO3, which direc

15 he activity of the protective axis of RAS by subretinal delivery of an AAV8 (Y733F)-ACE2 vector would

16 there were no notable safety concerns after subretinal delivery of an adeno-associated viral vector

17 Subretinal delivery of EDIT-101 in humanized CEP290 mice

18 Subretinal delivery of rAAV.sFLT-1 was well tolerated an

19 ssed long-term functional outcomes following subretinal delivery of the human melanopsin gene (OPN4)

20 The subretinal delivery procedure in this study was associat

21 Reticular pseudodrusen represent subretinal deposits that extend through the outer nuclea

22 nd, starting with loss of ellipsoid zone and subretinal deposits, followed by loss of external limiti

23 Among the 32 eyes with subretinal detachment, photoreceptor outer segment lengt

24 bility of and clinical response to a single, subretinal dose of human umbilical tissue-derived cells

25 ion, eyes were assigned to receive a single, subretinal dose of palucorcel (ranging from 6.0 x 10(4)

26 D, which is characterized by accumulation of subretinal drusen deposits and complement-driven inflamm

27 amyloid beta-peptide (Abeta) accumulates in subretinal drusen.

28 Subretinal drusenoid deposit presence and progression we

29 es (7.4%), drusen >=63 mum in 10 eyes (37%), subretinal drusenoid deposits (SDD) in 8 eyes (29.6%), c

30 In 19 eyes with subretinal drusenoid deposits (SDD) vs 47 eyes without S

31 l vascular features of eyes with and without subretinal drusenoid deposits (SDD), using swept-source

32 tients were enrolled, with 14 (46.7%) having subretinal drusenoid deposits (SDD).

33 grouped based on the presence or absence of subretinal drusenoid deposits (SDDs) for further analysi

34 ility to detect reticular pseudodrusen (RPD)/subretinal drusenoid deposits (SDDs) using 12x12-mm wide

35 meter) and large (>125 mu diameter), whereas subretinal drusenoid deposits (SDDs) were divided into d

36 s (drusen, pigmentary changes, late AMD, and subretinal drusenoid deposits [SDDs]).

37 ence tomography, the association between (1) subretinal drusenoid deposits and drusen, (2) RPE cell b

38 Subretinal drusenoid deposits are present in approximate

39 , hyporeflective foci within the drusen, and subretinal drusenoid deposits from OCT B-scans.

40 Subretinal drusenoid deposits were considered present at

41 ent (e.g., hyperreflective foci, drusen, and subretinal drusenoid deposits).

42 T1 in humans may underlie the development of subretinal drusenoid deposits, a hallmark of age-related

43 followed by choroid thickness in absence of subretinal drusenoid deposits, photoreceptor outer segme

44 t, reticular pseudodrusen (RPD) (also termed subretinal drusenoid deposits, SDD), which are located a

45 vessel volume are reduced in the presence of subretinal drusenoid deposits.

46 Yet, no subretinal electrical or chemical stimulation study has

47 However, the role of alphaB-crystallin in subretinal EMT and fibrosis is unknown.

48 histochemically to identify intraretinal and subretinal exudative cells.

49 Retinal folds and subretinal fibrin were identified in a greater proportio

50 lesions (10.7% [6/56]), and circumferential subretinal fibrosis (7.1% [4/56]).

51 als and hyperpigmentations (n = 9, 38%), and subretinal fibrosis (n = 15, 63%) with (n = 7, 47%) or w

52 Herein, we showed attenuation of subretinal fibrosis after regression of laser-induced ch

53 l macular atrophy and 22 (40.0%) had central subretinal fibrosis assessed as the principal cause for

54 potential therapeutic target for preventing subretinal fibrosis development in neovascular age-relat

55 on appeared to be macular atrophy in 60% and subretinal fibrosis in 40%.

56 Subretinal fibrosis is an end stage of neovascular age-r

57 Subretinal fibrosis showed limited flow in residual larg

58 D were retrospectively included when macular subretinal fibrosis was present.

59 Macular atrophy and subretinal fibrosis were the main reasons for 10 letter

60 In 9 eyes (38%, all with subretinal fibrosis), BCVA was significantly reduced (<2

61 etinal oxalate deposits, the pathogenesis of subretinal fibrosis, and exact factors influencing the o

62 otoreceptor layer with or without associated subretinal fibrosis; (2) an affected area, termed MacTel

63 phaB-crystallin was prominently expressed in subretinal fibrotic lesions in mice.

64 r with a Type 3 regression pattern, pre- and subretinal fibrovascular tissue consistent with PVR, and

65 nal fluid (AUC: 0.81; 95% CI: 0.81-0.86) and subretinal fluid (AUC 0.88; 95% CI: 0.85-0.91).

66 reated patients demonstrated a resolution of subretinal fluid (evaluation visit 1: 57% in the PDT gro

67 HSML-treated patients showed a resolution of subretinal fluid (evaluation visit: 1:48% in the PDT gro

68 OCT characteristics included subretinal fluid (n = 5), intraretinal fluid and cysts (

69 Related features included subretinal fluid (n = 9; 19%), cystoid retinal edema (n

70 The presence of subretinal fluid (odds ratio [OR], 1.98; 95% confidence

71 rrhage (OR, 1.44; 95% CI, 1.04-2.00), and no subretinal fluid (OR, 2.15; 95% CI, 1.06-4.40) predicted

72 raphy scan evaluation showed the presence of subretinal fluid (SRF) and pachychoroid supporting the d

73 s were defined, such as the baseline area of subretinal fluid (SRF) as measured on ultrasound images

74 orrected visual acuity (BCVA), resolution of subretinal fluid (SRF) demonstrated by optical coherence

75 ical characteristics, presence of persistent subretinal fluid (SRF) or intraretinal fluid (IRF), and

76 uantify intraretinal cystoid fluid (IRC) and subretinal fluid (SRF) was developed.

77 ial lesion complex was present in 86.4%, and subretinal fluid (SRF) was present in 76.3%.

78 f eyes had intraretinal fluid (IRF), 38% had subretinal fluid (SRF), 36% had subretinal pigment epith

79 resence of intraretinal cystoid fluid (IRC), subretinal fluid (SRF), and pigment epithelial detachmen

80 s (nanoliters) for intraretinal fluid (IRF), subretinal fluid (SRF), and pigment epithelial detachmen

81 wth of RPE/drusenoid material and persistent subretinal fluid (SRF), but also a RPE-independent visua

82 s included intraretinal cystoid fluid (IRC), subretinal fluid (SRF), pigment epithelial detachment, a

83 At 2 years, intraretinal fluid (IRF), subretinal fluid (SRF), sub-retinal pigment epithelium (

84 ina (NSR), drusen, intraretinal fluid (IRF), subretinal fluid (SRF), subretinal hyperreflective mater

85 ocation, and amount of intraretinal fluid or subretinal fluid (SRF); (4) presence, location, and amou

86 case series, % in literature, respectively): subretinal fluid (SRF; 30,9), chorioretinal folds (30,68

87 hickness [CST], intraretinal fluid [IRF], or subretinal fluid [SRF]) versus aflibercept (q8-week).

88 a vitrectomy alone with complete drainage of subretinal fluid achieves a high reattachment rate in th

89 D lens on slit lamp revealed the presence of subretinal fluid and few focal spots of retinal pigment

90 t reproducibility, particularly in eyes with subretinal fluid and greater choroidal thickness.

91 The presence of subretinal fluid and vitelliform material was noted in 7

92 Presence of subretinal fluid and vitelliform material were early fin

93 out persistent fluid (cystic intraretinal or subretinal fluid at all 4 initial visits).

94 e (OR 2.95, 95% CI 1.67-5.20, p < 0.001) and subretinal fluid at baseline (OR 3.17, 95% CI 1.62-6.18,

95 In 11 of 19 patients with intraretinal or subretinal fluid at baseline judged to be reversible, si

96 erence tomography data, only the presence of subretinal fluid at baseline was associated with poorer

97 cular volume (> 9.99 mm(3)), and presence of subretinal fluid at baseline were all associated with ea

98 reater total macular volume, and presence of subretinal fluid at baseline were associated with more r

99 idence interval [CI], 0.19-0.80; P = 0.010), subretinal fluid at final visit (OR, 0.41; 95% CI, 0.25-

100 e pigmented epithelial detachments, SMH, and subretinal fluid before and after SMH.

101 a shallow decline in acuity with increasing subretinal fluid but a much steeper decline with equival

102 s causes of retinal fluid, but was worst for subretinal fluid compared to intraretinal or sub-retinal

103 b-treated eyes had resolved intraretinal and subretinal fluid compared with aflibercept-treated eyes.

104 f RRD, area of RRD, foveal status, method of subretinal fluid drainage, retinal pigment epithelium (R

105 The subretinal fluid foci associated with MEK inhibitors hav

106 The mean maximum subretinal fluid height decreased from 126.6 mum at enro

107 Central subfield thickness, maximum subretinal fluid height, and maximum pigment epithelial

108 Changes in maximum subretinal fluid height, maximum pigment epithelial deta

109 ol may reduce central subfield thickness and subretinal fluid in eyes with persistent exudation despi

110 ual acuity and may demonstrate resolution of subretinal fluid in the absence of surgical intervention

111 asing subretinal hyperreflective material or subretinal fluid in this circumstance reduces vision fur

112 hs after oral treatment with eplerenone, the subretinal fluid increased significantly.

113 Persistent subretinal fluid is associated with increased subfoveal

114 ovement >=15 letters; and extensive baseline subretinal fluid modestly predicted CST <=250 mum (OR, 1

115 All 15 eyes (100%) showed subretinal fluid on iOCT.

116 n in the macula (57.4% vs. 67.5%, P = 0.01), subretinal fluid on OCT (33.3% vs. 70.7%, P = 0.01), and

117 Median time to complete resolution of subretinal fluid on OCT was 3.7 weeks (range, 2-12 weeks

118 undus was stopped and a disappearance of the subretinal fluid on SD-OCT was observed.

119 gion, as epiretinal membrane, macular edema, subretinal fluid or alterations of the outer layers of t

120 indication was recurrence of intraretinal or subretinal fluid or new hemorrhage.

121 reatment criteria relying on intraretinal or subretinal fluid or new hemorrhages may be expanded to i

122 ment, and 1 eye (12.5%) had minimal residual subretinal fluid parafoveally.

123 Intraoperative subretinal fluid persists under PFO tamponade with high

124 iagnosis of PSF was made by the detection of subretinal fluid pockets on OCT beyond 6 weeks after sur

125 t observed in the contralateral eye or after subretinal fluid resolution.

126 Subretinal fluid resolved in 13/18 eyes (72 %), and subr

127 Subretinal fluid resolved in 70% of pooled aflibercept-t

128 acteristics and variations in a patient with subretinal fluid secondary to a carotid cavernous fistul

129 hree-month follow-up, SD-OCT revealed subtle subretinal fluid that resolved spontaneously over time.

130 Matrix metallopeptidase-1 correlated with subretinal fluid volume (r = 0.50; P = .01).

131 Subretinal fluid volume on iOCT imaging was quantified.

132 th visual acuity outcome, and intraoperative subretinal fluid volume under PFO tamponade also may be

133 Increased intraoperative subretinal fluid volume under PFO tamponade trended towa

134 uced by >65% (P < 0.001) and central macular subretinal fluid volume was reduced by >99% in both arms

135 SD +/- 15.4) in which complete resolution of subretinal fluid was achieved after subthreshold micropu

136 Partial or complete resolution of subretinal fluid was achieved in 93% of patients.

137 Subretinal fluid was associated with better VA.

138 revealed a thicker choroidal thickness when subretinal fluid was present as compared to that observe

139 Subretinal fluid was present in 71% of patients, and PVD

140 At M01, subretinal fluid was seen in 28.5% intraretinal fluid in

141 er subretinal tissue complex and presence of subretinal fluid were associated with less GA developmen

142 normalizes faster after surgery in eyes with subretinal fluid when compared with eyes with intraretin

143 t or multiple recurrences of intraretinal or subretinal fluid while receiving monthly bevacizumab or

144 EDI-OCT disclosed macular subretinal fluid with an increase of choroidal thickness

145 y (BCVA) 20/40 or worse, and intraretinal or subretinal fluid with central foveal thickness (CFT) equ

146 On SS OCT, we observed subretinal fluid with elevation of the fovea (group 1) i

147 Inclusion criterion was a lack of subretinal fluid within the whole area of the central re

148 aseline OCT features (intraretinal cysts and subretinal fluid) are useful predictors of persistent di

149 total of 71 eyes with "resolved" (absence of subretinal fluid) chronic CSC at baseline and 36 months

150 tures (size, location, color, shape, related subretinal fluid) did not impact tumor control.

151 istent fluid by fluid type (intraretinal and subretinal fluid).

152 rs; 60% were over 2 mm in thickness, 63% had subretinal fluid, 84% caused symptoms, 57% had orange pi

153 rated less GA, less intraretinal fluid, more subretinal fluid, and less subretinal pigment epithelium

154 with gradual resolution of intraretinal- and subretinal fluid, and remained stable in 12 months.

155 scan for the presence of intraretinal fluid, subretinal fluid, and sub-retinal pigment epithelium flu

156 hickness at the foveal center of the retina, subretinal fluid, and subretinal tissue complex), visual

157 Group 2 comprised 7 eyes without subretinal fluid, but with intraretinal fluid.

158 sistant to treatments aimed at resolving the subretinal fluid, including some combination of anti-vas

159 coherence tomography (OCT) features such as subretinal fluid, intraretinal cysts and intraretinal fl

160 dence of CNV activity on SD OCT (presence of subretinal fluid, intraretinal fluid, and/or cystoid spa

161 (M24) for central subfield thickness (CST), subretinal fluid, intraretinal fluid, vitreoretinal inte

162 (30%), related to subfoveal scar, persistent subretinal fluid, reactive exudation, radiation maculopa

163 ps: anti-VEGF-resistant eyes with persistent subretinal fluid, subretinal hemorrhage, or macular edem

164 e impact on acuity of defined OCT changes in subretinal fluid, subretinal hyperreflective material, a

165 For detecting subretinal fluid, the investigator metrics were 0.946 (9

166 T), as well as associated features including subretinal fluid, were recorded before PDT and during fo

167 underwent PPV alone and complete drainage of subretinal fluid, with air, 20% sulfur hexafluoride (SF6

168 be associated with persistent postoperative subretinal fluid.

169 o were reviewed qualitatively for persistent subretinal fluid.

170 re used to evaluate MEK inhibitor-associated subretinal fluid.

171 teen tumors (86%) had complete resolution of subretinal fluid.

172 s (CRT) and the presence of intraretinal and subretinal fluid.

173 f DME, central subfield thickness (CST), and subretinal fluid.

174 nned outer nuclear layer and intraretinal or subretinal fluid.

175 for the presence/absence of intraretinal and subretinal fluid.

176 No widely accepted surgical technique for subretinal gene replacement therapy delivery in pediatri

177 nts aged 23 to 71 years underwent unilateral subretinal gene therapy for genetically confirmed choroi

178 Subretinal gene therapy in Abca4(-/-) mice using ECO/pRH

179 ate that the optimal intervention window for subretinal gene therapy is within the first 2 to 3 decad

180 %), iris trauma (62%), lens expulsion (54%), subretinal hemorrhage (51%), and choroidal hemorrhage (3

181 with RD after initial PPV were preoperative subretinal hemorrhage (odds ratio [OR], 5.73; P = 0.03),

182 1.48; P = 0.01), but not size of retinal or subretinal hemorrhage (P = 0.41).

183 Four of the 6 false negatives had large subretinal hemorrhage (SRH) and sensitivity improved to

184 aphs for the presence and size of retinal or subretinal hemorrhage at baseline and years 1 and 2.

185 able photographs, 724 (62.1%) had retinal or subretinal hemorrhage at baseline; 84.4% of hemorrhages

186 of 1078 participants (4.08%) had retinal or subretinal hemorrhage detected on 1- or 2-year photograp

187 nal fluid resolved in 13/18 eyes (72 %), and subretinal hemorrhage resolved in 6/8 eyes (75 %) respec

188 stant eyes with persistent subretinal fluid, subretinal hemorrhage, or macular edema after 4 anti-VEG

189 sing multicolor imaging included PEDs (26%), subretinal hemorrhages (40%), and drusen (66%).

190 d bilateral subhyaloid, outer plexiform, and subretinal hemorrhages after 2 minutes of chest compress

191 One eye had scattered subretinal hemorrhages external to the macula.

192 Most retinal or subretinal hemorrhages in eyes enrolled in CATT were les

193 etinal detachment, extending inferiorly, and subretinal hemorrhages.

194 pigment epithelium (RPE) fluid, and 66% had subretinal hyper-reflective material (SHRM).

195 Intraretinal and subretinal hyperreflective foci as seen on SD OCT correl

196 ), intraretinal fluid and cysts (n = 1), and subretinal hyperreflective material (n = 7).

197 Worse baseline VA and presence of subretinal hyperreflective material (SHRM) at month 12 w

198 The range of subretinal hyperreflective material (SHRM) seen in macul

199 Foveal choroidal thickness (FCT), subretinal hyperreflective material (SHRM), and pigment

200 retinal fluid (IRF), subretinal fluid (SRF), subretinal hyperreflective material (SHRM), retinal pigm

201 Subretinal hyperreflective material disappeared by 5 yea

202 Increasing subretinal hyperreflective material or subretinal fluid

203 Subretinal hyperreflective material resulting from acqui

204 of defined OCT changes in subretinal fluid, subretinal hyperreflective material, and loss of externa

205 Subretinal hyperreflective material, macular hemorrhage,

206 MNV, subretinal hyperreflective material, pigment epithelial

207 ssion to type A, followed by RPE erosion and subretinal hyperreflective material, then type B and typ

208 h steeper decline with equivalent increasing subretinal hyperreflective material.

209 -1beta receptor preserved choroid, decreased subretinal hypoxia, and prevented RPE/photoreceptor deat

210 The Alpha AMS subretinal implant improved visual performance in 5 of 6

211 ing eye (<=20/200) of each subject underwent subretinal implantation of a single 3.5x6.25 mm CPCB-RPE

212 ients underwent a pars plana vitrectomy with subretinal implantation of human amniotic membrane (hAM)

213 recorded in rats implanted with photovoltaic subretinal implants.

214 Apart from steroid-responsive subretinal inflammation in patients at the higher doses,

215 aytime vision in conditions characterized by subretinal inflammation, such as AMD and RP.

216 s, retinal functional deficits, and signs of subretinal inflammation.

217 lacking heparin binding transduce retina by subretinal injection and display a remarkable ability to

218 llowing somatic knockout of LRRTM4 in BCs by subretinal injection and electroporation of CRISPR/Cas9,

219 To assess the safety of rAAV.sFlt-1 subretinal injection in neovascular age-related macular

220 Compared with subretinal injection in rats of RGX-314, an AAV8 vector

221 n a phase 1 clinical trial received a second subretinal injection in their contralateral eye in a fol

222 Treatment consisted of a subretinal injection of 0.1 mL of a gene therapy solutio

223 Intervention was bilateral, subretinal injection of 1.5 x 10(11) vector genomes of v

224 Here, we show, in adult mice, that a subretinal injection of a lentivirus expressing an ABE a

225 dose-escalation study involving a unilateral subretinal injection of a recombinant adeno-associated v

226 Subretinal injection of AAV8-sCX3CL1 significantly prolo

227 Participants received a subretinal injection of palucorcel, 3.0 x 10(5) cells in

228 Patients received a subretinal injection of rAAV2-CB-hRPE65 in the poorer-se

229 Subretinal injection of VN in the second eye of phase 1

230 ofile was consistent with vitrectomy and the subretinal injection procedure, and no deleterious immun

231 ive microscope-integrated OCT allowed proper subretinal injection with avoidance of excessive foveal

232 Subretinal injection with pars plana vitrectomy was well

233 retinal pigment epithelium (RPE) tissue via subretinal injection, providing a highly promising nanop

234 Subretinal injection, the preferred route of delivery fo

235 (1 x 10(11) vector genomes) rAAV.sFLT-1 via subretinal injection.

236 aled the efficacy and durability of a 1-time subretinal injection.

237 mutations, 1.71-4.58 years after the initial subretinal injection.

238 All patients tolerated subretinal injections and there were no treatment-relate

239 of the retina (preretinal, intraretinal, and subretinal layers).

240 Mean thickness of the subretinal lesion complex (measured in microns +/- stand

241 Subretinal lesion components were common in areas of sca

242 (3) Subretinal lesion features covered 31% of GA, 42% of NGA

243 -domain OCT (SD-OCT)-determined features and subretinal lesion thicknesses at sites of macular scar o

244 ace need, likely leading to the formation of subretinal lesions and reduced visual function.

245 ial mechanisms leading to the development of subretinal lesions and vision loss.SIGNIFICANCE STATEMEN

246 e deposits appeared as focal hyperreflective subretinal lesions on OCT imaging and were hyperautofluo

247 These flat, subretinal lesions were located in the mid or far periph

248 Of these, 5 appeared de novo in a subretinal location, with photographic evidence of no pr

249 in both SW-AF and NIR-AF corresponded to the subretinal macrophages fully packed with pigment granule

250 2, 78% were preceded by thick drusen, 54% by subretinal macular neovascularization (MNV), and 22.5% b

251 in IMPG1/IMPG2 develop visual deficits with subretinal material accumulation, highlighting the criti

252 approaches that disrupt the photoreceptors' subretinal microenvironment.

253 reas of thick drusen, areas with and without subretinal MNV lesion, and areas without detectable OCT

254 Inhibiting subretinal MP accumulation or Il-1beta might protect the

255 Our results strongly suggest that subretinal MP accumulation participates in the observed

256 ression of VEGF in the retina of mice causes subretinal neovascularization.

257 Both eyes showed improvement in subretinal or intraretinal fluid on OCT.

258 essary but potentially useful in identifying subretinal pathology and confirming implant location.

259 RF), 38% had subretinal fluid (SRF), 36% had subretinal pigment epithelium (RPE) fluid, and 66% had s

260 tinal fluid, more subretinal fluid, and less subretinal pigment epithelium fluid (all P < 0.01).

261 y (presence of intraretinal, subretinal, and subretinal pigment epithelium fluid; thickness at the fo

262 Intraoperative OCT was used to guide subretinal placement in 9 cases.

263 ed, including area of GA covered by implant, subretinal position of implant, duration of surgery, and

264 ture development of a neurotransmitter-based subretinal prosthesis offering more naturalistic vision

265 d near-infrared-light-sensitive photovoltaic subretinal prosthesis.

266 a suggest that melanopsin gene therapy via a subretinal route may be a viable and stable therapeutic

267 (6%), a choroidal neovascularization-related subretinal scar in 3 (19%), and loss of ellipsoid zone a

268 choroidal or retinal tumor, vitreous seed or subretinal seed, or extrascleral extension.

269 mors, in 6/6 eyes), and 100% of vitreous and subretinal seeds regressed, with 100% globe salvage.

270 l was delivered successfully to the targeted subretinal site using a novel delivery system and suprac

271 P3HT NPs spread out over the entire subretinal space and promote light-dependent activation

272 s cause microglial dominant migration to the subretinal space as a protective response, whereas the a

273 y transduce the retina when delivered to the subretinal space but show limited success when delivered

274 ulation of lactate levels in the RPE and the subretinal space is essential for the viability and func

275 the homeostatic elimination of MPs from the subretinal space mediated by thrombospsondin-1 (TSP-1) a

276 f IMPG2, IMPG1 abnormally accumulated at the subretinal space need, likely leading to the formation o

277 the CRRY coding sequence (AAV-CRRY) into the subretinal space of 4-wk-old Abca4(-/-) mice.

278 eGFP transgenic mice were injected into the subretinal space of LCA8-like model neonatal mice.

279 ed photoreceptor-like cells (CiPCs) into the subretinal space of rod degeneration mice (homozygous fo

280 ns with displacement of retinal neurons into subretinal space to severe hypocellularity and ultrastru

281 outer aspect ofphotoreceptor cells (i.e.,the subretinal space), which is crucially involved in the pa

282 , microglia from both pools relocated to the subretinal space, an inducible disease-associated niche

283 generation, retinal microglia migrate to the subretinal space, an inducible disease-associated niche,

284 s membrane, loss of photoreceptors, cells in subretinal space, and a reduction of choroidal vessels.

285 When cells were sequestered in the subretinal space, palucorcel was well tolerated and may

286 (6) HuCNS-SCs were infused directly into the subretinal space, superotemporal to the fovea near the j

287 migration of retinal cells into voids in the subretinal space.

288 retinopathy (CSCR), fluid accumulates in the subretinal space.

289 ed to evaluate preretinal, intraretinal, and subretinal stresses during repetitive shaking.

290 rs3750846 SNP at the ARMS2/HTRA1 locus with subretinal/sub-retinal pigment epithelial (RPE) hemorrha

291 ion of the SNP at the ARMS2/HTRA1 locus with subretinal/sub-RPE hemorrhage and poorer visual acuity a

292 Thicker subretinal tissue complex and presence of subretinal flu

293 rmally thin retina, greater thickness of the subretinal tissue complex on OCT, and subfoveal geograph

294 -retinal pigment epithelium (RPE) fluid, and subretinal tissue complex thickness decreased in all tre

295 center of the retina, subretinal fluid, and subretinal tissue complex), visual acuity, and age.

296 etina, 5 mum (21) for SRF, 125 mum (107) for subretinal tissue complex, 11 mum (33) for SHRM, and 103

297 mong NFS eyes, mean thickness of the retina, subretinal tissue complex, and total retina did not chan

298 g photoreceptor replacement strategies using subretinal transplantation of photoreceptor precursor ce

299 In the latter scenario, subretinal transplantation places donor cells beneath an

300 Our study suggests that in BVMD, subretinal vitelliform material accumulation leads to a